Back to today’s briefing

Story perspectives

Study: Stopping GLP-1 Medications Raises Cardiovascular Risks

3/21/2026

32 2

Summary

Story summary

A new BMJ Medicine study finds stopping glucagon-like peptide-1 (GLP-1) medications like Ozempic and Mounjaro increases cardiovascular risk.
The study analyzed more than 333,000 veterans with type 2 diabetes.
Risks of heart attack and stroke rose 4% within six months and 22% after two years.
Experts urge insurers to recognize the long-term necessity of continuous GLP-1 use to prevent harm.

1 of 1

Story summary

A new BMJ Medicine study finds stopping glucagon-like peptide-1 (GLP-1) medications like Ozempic and Mounjaro increases cardiovascular risk.
The study analyzed more than 333,000 veterans with type 2 diabetes.
Risks of heart attack and stroke rose 4% within six months and 22% after two years.
Experts urge insurers to recognize the long-term necessity of continuous GLP-1 use to prevent harm.